B1CTcu5: A frog-derived brevinin-1 peptide with anti-tuberculosis activity
- Resource Type
- Authors
- Leny Jose; R. Ajay Kumar; Tessy Thomas Maliekal; K. Santhosh Kumar; Parvin Abraham
- Source
- Peptides. 132
- Subject
- Tuberculosis
Physiology
Antimicrobial peptides
Antitubercular Agents
030209 endocrinology & metabolism
Peptide
Drug resistance
Microbial Sensitivity Tests
Biochemistry
Amphibian Proteins
Microbiology
Mycobacterium tuberculosis
03 medical and health sciences
Cellular and Molecular Neuroscience
Structure-Activity Relationship
0302 clinical medicine
Endocrinology
medicine
Animals
Humans
Cytotoxicity
Cells, Cultured
chemistry.chemical_classification
biology
Chemistry
Macrophages
biology.organism_classification
medicine.disease
In vitro
Anura
030217 neurology & neurosurgery
Intracellular
Antimicrobial Cationic Peptides
- Language
- ISSN
- 1873-5169
Tuberculosis (TB) is a devastating infectious disease that causes a high rate of mortality. Drugs with new modes of action are needed to overcome this scenario. Cationic antibacterial peptides can serve as a potential alternative to existing TB drugs as they target the entire bacterial membrane for activity, thereby reducing the probability of development of drug resistance. In this study, we report anti-tuberculosis activity of B1CTcu5, a peptide that belongs to brevinin-1 family of antimicrobial peptides. This peptide possesses potent in vitro inhibitory activity against M. tuberculosis at 12.5 μg/mL but was not active against M. smegmatis. B1CTcu5 successfully eliminated intracellular mycobacteria without inducing cytotoxicity to the human macrophages at the concentrations tested. This peptide can be used as a template to design peptide-based anti-tubercular agents.